Latest News

Cancer Killers

Fusion Pharmaceuticals Announces Pricing of Initial Public Offering.

26th June 2020

HAMILTON, ONTARIO and Boston. 25 June 2020.  Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public offering of 12,500,000 common shares at a public […]

Read More
Alflorex Zenflore V2

Novozymes acquires PrecisionBiotics Group.

25th June 2020

25 June 2020.  Seroba’s portfolio company, PrecisionBiotics Group has been acquired by Novozymes. Based in Cork, Ireland, PrecisionBiotics Group holds a leading position within probiotics for human gut health.  Its products include the regular award-winning Alflorex for digestive health and […]

Read More
The Big Taboo

New U.K. Study Offers Good News to Sufferers During World Continence Week

22nd June 2020

A new study has been published in the Journal of Medical Economics demonstrating that INNOVO® is a compelling and cost-effective treatment option for Stress Urinary Incontinence in adult females. (Authors: Ash Monga, Mehdi Javanbakht, Ph.D.) You can read details of […]

Read More
Shorla Pharma

Shorla Pharma Closes $8.3m Series A Funding Round

3rd June 2020

Dublin and Clonmel, Ireland. June 4, 2020.   Shorla Pharma Limited (‘Shorla’), an Irish specialty pharmaceutical company has today announced the completion of a Series A investment of $8.3m.  The financing was led by Seroba Life Sciences (‘Seroba’), a European Venture […]

Read More

Quanta provides compact dialysis systems to NHS to support increased need caused by COVID-19 pandemic

1st June 2020

Alcester, Warwickshire, UK, 01 June 2020:  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology innovation company, today announced that it has been proudly supporting the ongoing National Health Service (NHS) COVID-19 response for emergency […]

Read More

Fusion Pharmaceuticals Appoints New Chief Medical Officer

23rd March 2020

23 March 2020.  Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers, today announced the appointment of James J. O’Leary, M.D., as chief medical […]

Read More
Endotronix 025 Lo (002)

Endotronix Announces Enrollment of the First Patients in the PROACTIVE-HF Pivotal Trial

18th February 2020

LISLE, IL – February 18, 2020 – Seroba’s portfolio company, Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), today announced the enrollment of the first two patients in the PROACTIVE-HF […]

Read More
Cancer Killers

Fusion Announces the Appointment of Pablo J. Cagnoni, M.D. to its Board of Directors

6th February 2020

Boston, MA & Hamilton, February 6, 2020.   Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing targeted alpha therapeutics, has announced the appointment of Pablo J. Cagnoni, M.D., to the board of directors. Dr. Cagnoni’s appointment as […]

Read More
The Big Taboo

Atlantic Therapeutics Announces FDA Clearance for Over-the-Counter Use of INNOVO®

6th February 2020

GALWAY, Ireland.  6 February 2020.  Seroba’s portfolio  company, Atlantic Therapeutics, a global medical device manufacturer, today announced that the U.S. Food and Drug Administration (FDA) has granted over-the-counter (OTC) clearance to INNOVO®, a non-invasive, clinically proven and wearable device for […]

Read More
Cancer Killers

Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board

13th January 2020

Hamilton, ON & Boston, MA – January 13, 2020 – Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced an investment commitment of up to US$20 million from Canada Pension Plan Investment Board […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top